Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000279175 is a long non-coding RNA gene transcribed antisense to parvin beta (PARVB). Natural antisense transcripts like this regulate gene expression by mechanisms such as transcriptional interference, RNA masking, and modulation of mRNA stability for the overlapping sense gene. While the PARVB protein-coding gene is implicated in various biological processes (actin cytoskeleton, cell adhesion, migration, cancer progression), the antisense lncRNA has no established function as a therapeutic target or biomarker and is not considered a classical receptor, enzyme, transporter, or drug target in current biomedical practice[5][3][1]. If you are looking for a classical receptor or protein target, this entry is not suitable; it refers to a regulatory RNA transcript rather than a protein-coding drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to parvin beta (ENSG00000279175).